Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma

Kristensen, 1997, Epithelial ovarian carcinoma, Lancet, 349, 113, 10.1016/S0140-6736(96)06071-0 Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med., 5, 157, 10.1038/5517 Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest., 104, 155, 10.1172/JCI6926 Cuello, 2001, Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells, Gynecol. Oncol., 81, 380, 10.1006/gyno.2001.6194 Vignati, 2002, Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs, Eur. J. Cancer, 38, 177, 10.1016/S0959-8049(01)00345-8 Siervo-Sassi, 2003, Physiological and molecular effects of Apo2L/TRAIL and cisplatin ovarian carcinoma cell lines, Cancer Lett., 190, 61, 10.1016/S0304-3835(02)00579-7 Keane, 1999, Chemotherapy augments TRAIL-induced apoptosis in breast cell lines, Cancer Res., 59, 734 Pan, 1998, TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling, FEBS Lett., 424, 41, 10.1016/S0014-5793(98)00135-5 Mitsiades, 2001, TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications, Blood, 98, 795, 10.1182/blood.V98.3.795 Mitsiades, 2001, Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5, Cancer Res., 61, 2704 Ahmad, 2000, TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention, Oncogene, 19, 3363, 10.1038/sj.onc.1203679 Lincz, 2001, TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy, Leukemia, 15, 1650, 10.1038/sj.leu.2402251 Nagane, 2000, Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res., 60, 847 FIGO International Federation of Gynecology and Obstetrics, 1987, Changes in definitions of clinical staging for cancer of the cervix and ovary, Am. J. Obstet. Gynecol., 156, 236 Koornstra, 2003, Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas, J. Pathol., 200, 327, 10.1002/path.1364 Spierings, 2003, Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors, Clin. Cancer Res., 9, 3397 Mitsiades, 2000, Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand, Cancer Res., 60, 4122 De Jong, 2001, Death receptor ligands, in particular TRAIL, to overcome drug resistance, Cancer Metastasis Rev., 20, 51, 10.1023/A:1013112624971 Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8 Wajant, 2002, TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy, Apoptosis, 7, 449, 10.1023/A:1020039225764 Kelley, 2001, Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety, J. Pharmacol. Exp. Ther., 299, 31 Lawrence, 2001, Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, Nat. Med., 7, 383, 10.1038/86397 Tanaka, 2000, Expression and antitumor effects of TRAIL in human cholangiocarcinoma, Hepatology, 32, 523, 10.1053/jhep.2000.9716 Shigeno, 2003, Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation, Oncogene, 22, 1653, 10.1038/sj.onc.1206139 Dejosez, 2000, Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan, Cell Death Differ., 7, 1127, 10.1038/sj.cdd.4400746 Naka, 2002, Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice, Cancer Res., 62, 5800 Chawla-Sarkar, 2002, IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis, J. Immunol., 15, 847, 10.4049/jimmunol.169.2.847 Di Pietro, 2001, Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1, Blood, 97, 2596, 10.1182/blood.V97.9.2596 Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res., 61, 1645 Griffin, 2003, Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells, Gynecol. Oncol., 89, 37, 10.1016/S0090-8258(03)00006-4 Nimmanapalli, 2001, Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels, Cancer Res., 61, 759 Sun, 2000, Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells, Cancer Res., 60, 7149 Wen, 2000, Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells, Blood, 96, 3900, 10.1182/blood.V96.12.3900 Wu, 1997, KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene, Nat. Genet., 17, 141, 10.1038/ng1097-141 Sheikh, 1999, The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract, Oncogene, 18, 4153, 10.1038/sj.onc.1202763 Takimoto, 2000, Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site, Oncogene, 19, 1735, 10.1038/sj.onc.1203489 Meng, 2001, p53-Independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma, Exp. Cell Res., 262, 154, 10.1006/excr.2000.5073 Lee, 2001, Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma, Oncogene, 20, 399, 10.1038/sj.onc.1204103 Lee, 1999, Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers, Cancer Res., 59, 5683 Shin, 2001, Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers, Cancer Res., 61, 4942 Bennett, 1998, Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis, Science, 282, 290, 10.1126/science.282.5387.290 Jones, 1999, TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1, J. Immunol., 162, 1042, 10.4049/jimmunol.162.2.1042 Zhang, 2000, Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells, J. Immunol., 164, 3961, 10.4049/jimmunol.164.8.3961 Sträter, 2002, TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections, Gastroenterology, 122, 659, 10.1053/gast.2002.31889 Sträter, 2002, Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter, Clin. Cancer Res., 8, 3734 Lancaster, 2003, High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival, Clin. Cancer Res., 9, 762 Herrnring, 2000, Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumours, Histochem. Cell Biol., 113, 189, 10.1007/s004180050438